


In the Claims:

1. (Previously Presented) A compound of formula (I):



wherein

R^1 is selected from C_{1-6} alkyl substituted by one to three groups independently selected from oxo, cyano and $-S(O)_pR^4$, and a C_{3-7} cycloalkyl substituted by one to three groups independently selected from oxo, cyano, $-S(O)_pR^4$, OH, halogen, C_{1-6} alkoxy, $-NR^5R^6$, $-CONR^5R^6$, $-NCOR^5$, $-COOR^5$, $-SO_2NR^5R^6$, $-NHSO_2R^5$ and $-NHCONHR^5$,

R^2 is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl, or $(CH_2)_mR^1$ and R^2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally containing one or two additional heteroatoms independently selected from oxygen, sulphur and $N-R^7$, wherein the ring is optionally substituted by one or two groups independently selected from oxo, C_{1-6} alkyl, halogen and trifluoromethyl;

R^3 is the group $-CO-NH-(CH_2)_r-R^8$ or $-NH-CO-R^9$;

R^4 is selected from hydrogen, C_{1-6} alkyl, heterocyclyl optionally substituted by C_{1-4} alkyl, and phenyl wherein the phenyl is optionally substituted by up to two groups independently selected from C_{1-6} alkoxy, C_{1-6} alkyl and halogen;

R⁵ is selected from hydrogen, C₁₋₆alkyl and phenyl wherein the phenyl group is optionally substituted by up to two substituents selected from C₁₋₆alkyl and halogen,

R⁶ is selected from hydrogen and C₁₋₆alkyl, or

R⁵ and R⁶, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic or heteroaryl ring optionally containing up to one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring is optionally substituted by up to two C₁₋₆alkyl groups;

R⁷ is selected from hydrogen and methyl;

when r is 0 to 2, R⁸ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, CONHR⁵, phenyl optionally substituted by R¹⁰ and/or R¹¹, heteroaryl optionally substituted by R¹⁰ and/or R¹¹ and heterocyclyl optionally substituted by R¹⁰ and/or R¹¹, and

when r is 2, R⁸ is additionally selected from C₁₋₆alkoxy, NHCOR⁵, NHCONHR⁵, NR⁵R⁶ and OH;

R⁹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_s-C₃₋₇cycloalkyl, trifluoromethyl, -(CH₂)_tphenyl optionally substituted by R¹² and/or R¹³, -(CH₂)_t heteroaryl optionally substituted by R¹² and/or R¹³, -(CH₂)_theterocyclyl optionally substituted by R¹² and/or R¹³ and -(CH₂)_tfused bicyclyl optionally substituted by R¹² and/or R¹³;

R¹⁰ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -CONR⁶R¹⁴, -NHCOR¹⁴, -SO₂NHR¹⁴, -NHSO₂R¹⁴, halogen, trifluoromethyl, -X-(CH₂)_j-phenyl optionally substituted by one or more halogen atoms or C₁₋₆alkyl groups, -X-(CH₂)_j-heterocyclyl or -X-(CH₂)_j-heteroaryl wherein the heterocyclyl or heteroaryl group is optionally substituted by one or more substituents selected from C₁₋₆alkyl,

R¹¹ is selected from C₁₋₆alkyl and halogen, or

when R¹⁰ and R¹¹ are ortho substituents, then together with the carbon atoms to which they are bound, R¹⁰ and R¹¹ may form a five- or six-membered

saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R¹⁰ and R¹¹ optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R¹² is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)₅-C₃₋₇cycloalkyl, -CONR¹⁵R¹⁶, -NHCOR¹⁶, -SO₂NHR¹⁵, -NHSO₂R¹⁶, halogen, -(CH₂)_kNR¹⁷R¹⁸, oxy, trifluoromethyl, phenyl optionally substituted by one or more R¹³ groups and heteroaryl wherein the heteroaryl is optionally substituted by one or more R¹³ groups,

R¹³ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl and -NR¹⁷R¹⁸, or

R¹² and R¹³, together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R¹² and R¹³ optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R¹⁴ is selected from hydrogen and C₁₋₆alkyl;

R¹⁵ is selected from hydrogen, C₁₋₆alkyl and phenyl wherein the phenyl group may be optionally substituted by one or more R¹³ groups,

R¹⁶ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁵ and R¹⁶, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R⁷, wherein the ring is optionally substituted by up to two C₁₋₆alkyl groups;

R¹⁷ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)₅-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁸ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁷ and R¹⁸, together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R⁷, wherein the ring may contain up to one double bond and the ring is optionally substituted by one or more R¹⁹ groups;

R^{19} is selected from C_{1-6} alkyl, oxy, $-CH_2OC_{1-6}$ alkyl, trichloromethyl and $-N(C_{1-6}alkyl)_2$;

X is selected from -O- and a bond;

U is selected from methyl and halogen;

W is selected from methyl and chlorine;

V and Y are each selected independently from hydrogen, methyl and halogen;

m is selected from 0, 1, 2, 3 and 4, and when m is 1 to 4 at least one carbon atom of the resulting carbon chain is optionally substituted with one or two groups selected independently from C_{1-6} alkyl, and wherein the C_{1-6} alkyl group is optionally substituted by up to three OH groups;

n, p, r and j are independently selected from 0, 1 and 2;

q and k are independently selected from 0, 1, 2 and 3; and

s and t are independently selected from 0 and 1;

or a pharmaceutically acceptable derivative thereof.

2. (Original) A compound according to claim 1 wherein R^1 is selected from C_{2-6} alkyl substituted by one or two groups independently selected from oxo, cyano and $-S(O)_tR^4$, and C_{3-6} cycloalkyl optionally substituted by one or two groups independently selected from OH and cyano.

3. (Previously Presented) A compound according to claim 1 wherein R^2 is hydrogen.


4. (Previously Presented) A compound according to claim 1 wherein R^8 is C_{3-6} cycloalkyl.

5. (Previously Presented) A compound according to claim 1 wherein m is selected from 0 and 1 and wherein the carbon chain is optionally substituted by one or two methyl groups which are optionally substituted by OH.

6. (Original) A compound according to claim 1 as defined in any one of Examples 1 to 11, or a pharmaceutically acceptable derivative thereof.

7. (Previously Presented) A process for preparing a compound according to claim 1 which comprises:

(a) reacting a compound of formula (XXII)




wherein R^1 , R^2 , U, W, V, Y, m and n are as defined in claim 1, with a compound of formula (XXIII)



wherein R^8 and r are as defined in claim 1, under amide forming conditions optionally converting the acid compound (XXII) to an activated form of the acid before reaction with the amine compound (XXIII);

(b) reacting a compound of formula (XXIV)




wherein R^3 , U, W, V, Y and n are as defined in claim 1,
 with a compound of formula (XXV)




wherein R^1 , R^2 , m and n are as defined in claim 1,
 under amide forming conditions;

(c) reacting a compound of formula (XXVI)




wherein R^3 , U, W, V, Y and n are as defined in claim 1,
 with a compound of formula (XXV) as defined above;

(d) reacting a compound of formula (XXVII)




wherein W, V, Y and R³ are as defined in claim 1,
with a compound of formula (XXVIII)



wherein R¹, R², U, m and n are as defined above and hal is halogen, in the presence of
a catalyst; or

(e) reacting a compound of formula (XXIX)



wherein R¹, R², U, W, V, Y, m and n are as defined in claim 1,
with a compound of formula (XXX)



wherein R⁹ is as defined in claim 1,

under amide forming conditions optionally converting the acid compound (XXX)
to an activated form of the acid before reaction with the amine compound
(XXIX).


8. (Currently amended) A pharmaceutical composition comprising at least one compound according to ~~any~~ claim 1 or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.

9 to 13. (cancelled)

14. (Previously Presented) A compound according to claim 1 wherein R^3 is the group $-\text{CO}-\text{NH}-(\text{CH}_2)_t-\text{R}^8$.

15. (Previously Presented) A compound according to claim 14 wherein R^8 is selected from C_{1-4} alkyl or C_{3-6} cycloalkyl, CONHR^5 , phenyl optionally substituted by R^{10} and/or R^{11} , thiazolyl, pyrazolyl, thiadiazolyl, or pyridyl all optionally substituted by R^{10} and/or R^{11} .

16. (Previously Presented) A compound of formula (I):



wherein

R^1 is a C_{3-7} cycloalkyl;

R^2 is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl, or

$(CH_2)_m R^1$ and R^2 , together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally containing one or two additional heteroatoms independently selected from oxygen, sulphur and $N-R^7$, wherein the ring is optionally substituted by one or two groups independently selected from oxo, C_{1-6} alkyl, halogen and trifluoromethyl;

R^3 is the group $-CO-NH-(CH_2)_r-R^8$ or $-NH-CO-R^9$;

R^4 is selected from hydrogen, C_{1-6} alkyl, heterocyclyl optionally substituted by C_{1-4} alkyl, and phenyl wherein the phenyl is optionally substituted by up to two groups independently selected from C_{1-6} alkoxy, C_{1-6} alkyl and halogen;

R^5 is selected from hydrogen, C_{1-6} alkyl and phenyl wherein the phenyl group is optionally substituted by up to two substituents selected from C_{1-6} alkyl and halogen,

R^6 is selected from hydrogen and C_{1-6} alkyl, or

R^5 and R^6 , together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic or heteroaryl ring optionally containing up to one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring is optionally substituted by up to two C_{1-6} alkyl groups;

R^7 is selected from hydrogen and methyl;

when r is 0 to 2, R^8 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $CONHR^5$, phenyl optionally substituted by R^{10} and/or R^{11} , heteroaryl optionally substituted by R^{10} and/or R^{11} and heterocyclyl optionally substituted by R^{10} and/or R^{11} , and

when r is 2, R^8 is additionally selected from C_{1-6} alkoxy, $NHCOR^5$, $NHCONHR^5$, NR^5R^6 and OH ;

R^9 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_s-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_t$ phenyl optionally substituted by R^{12} and/or R^{13} ,

$-(CH_2)_t$ heteroaryl optionally substituted by R^{12} and/or R^{13} , $-(CH_2)_t$ heterocyclyl optionally substituted by R^{12} and/or R^{13} and $-(CH_2)_t$ fused bicyclyl optionally substituted by R^{12} and/or R^{13} ;

R^{10} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-CONR^6R^{14}$, $-NHCOR^{14}$, $-SO_2NHR^{14}$, $-NHSO_2R^{14}$, halogen, trifluoromethyl, $-X-(CH_2)_j$ -phenyl optionally substituted by one or more halogen atoms or C_{1-6} alkyl groups, $-X-(CH_2)_j$ -heterocyclyl or $-X-(CH_2)_j$ -heteroaryl wherein the heterocyclyl or heteroaryl group is optionally substituted by one or more substituents selected from C_{1-6} alkyl,

R^{11} is selected from C_{1-6} alkyl and halogen, or

when R^{10} and R^{11} are ortho substituents, then together with the carbon atoms to which they are bound, R^{10} and R^{11} may form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R^{10} and R^{11} optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R^{12} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_5-C_{3-7}$ cycloalkyl, $-CONR^{15}R^{16}$, $-NHCOR^{16}$, $-SO_2NHR^{15}$, $-NHSO_2R^{16}$, halogen, $-(CH_2)_kNR^{17}R^{18}$, oxy, trifluoromethyl, phenyl optionally substituted by one or more R^{13} groups and heteroaryl wherein the heteroaryl is optionally substituted by one or more R^{13} groups,

R^{13} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl and $-NR^{17}R^{18}$, or

R^{12} and R^{13} , together with the carbon atoms to which they are bound, form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R^{12} and R^{13} optionally contains one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R^{14} is selected from hydrogen and C_{1-6} alkyl;

R^{15} is selected from hydrogen, C_{1-6} alkyl and phenyl wherein the phenyl group may be optionally substituted by one or more R^{13} groups,

R^{16} is selected from hydrogen and C_{1-6} alkyl, or

R¹⁵ and R¹⁶, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R⁷, wherein the ring is optionally substituted by up to two C₁₋₆alkyl groups;

R¹⁷ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)₈-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁸ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁷ and R¹⁸, together with the nitrogen atom to which they are bound, form a three- to seven-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R⁷, wherein the ring may contain up to one double bond and the ring is optionally substituted by one or more R¹⁹ groups;

R¹⁹ is selected from C₁₋₆alkyl, oxy, -CH₂OC₁₋₆alkyl, trichloromethyl and -N(C₁₋₆alkyl)₂;

X is selected from -O- and a bond;

U is selected from methyl and halogen;

W is selected from methyl and chlorine;

V and Y are each selected independently from hydrogen, methyl and halogen;

m is selected from 1, 2, 3 and 4, and wherein at least one carbon atom of the resulting carbon chain is substituted with one or two groups selected independently from a C₁₋₆alkyl substituted with one to three OH groups;

n, p, r and j are independently selected from 0, 1 and 2;

q and k are independently selected from 0, 1, 2 and 3; and

s and t are independently selected from 0 and 1;

or a pharmaceutically acceptable derivative thereof.

17. (New) A pharmaceutical composition comprising at least one compound according to claim 16 or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.